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IntroductIon
The primary goal of this review was to revisit the concept of 
gastroesophageal reflux disease (GERD). The previously vari-
able definition of GERD was finally standardized in 2006 with 
the Montreal Consensus, which states that GERD is “a condi-
tion that develops when the reflux of stomach contents into the 
esophagus causes troublesome symptoms and/or complications” 
[1]. The Montreal Definition of GERD encapsulates most even-
tualities, from patients with reflux esophagitis with or without 
symptoms (the latter actually accounting for close to 40% [2] of 
such patients in Western populations, and possibly a much higher 
proportion in Asian populations [3]) to those with symptoms but 
no other findings. The latter, purely symptom-based definition of 
GERD provided a rationale for treatment with acid-suppressive 
medications without the need for cumbersome investigations of 
symptom etiology, thus enhancing management of the substantial 
symptom burden in these patients [4–6]. The Montreal Definition 
also acknowledges that reflux contents other than acid can cause 
symptoms. However, the degree of the complexity of the relation-
ship between symptoms and reflux was perhaps not fully appreci-
ated at the time of its development. The situation has been further 
complicated by the subsequent, comprehensive categorization of 
a range of functional esophageal disorders that are indistinguish-
able from GERD without substantial investigation [7]. As part of 
our revisiting the concept of GERD, we recap our current under-
standing of the relationship between suspected GERD symptoms 
and reflux (or lack thereof), with a focus on the persisting clini-
cal challenge and possible mechanisms of reflux hypersensitivity 
and functional heartburn. Finally, we discuss the implications 
of these findings for our current assumptions about suspected 
GERD symptoms, including whether treating GERD as a com-
posite disease entity may now be a barrier to more precise patient 
management.
Are typIcAl symptoms IndIcAtIve of AcId 
reflux?
Even the “typical” symptoms of GERD, defined in the Montreal 
Consensus as heartburn and regurgitation, may not be that typical, 
with their diagnostic value questioned in the Diamond study [8]. 
In this study, consecutive patients presenting to their family prac-
titioner with upper gastrointestinal (GI) symptoms were asked 
to identify their most troublesome symptom. These data were 
then analyzed according to whether or not patients had GERD 
based on objective investigation, defined as either the presence of 
reflux esophagitis, pathologic esophageal acid exposure (pH > 4 
for > 5.5% of the time over a 24 h period), or a positive symptom 
association probability (SAP) for acid reflux. Tellingly, only 49% 
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of patients with objectively defined GERD selected heartburn or 
regurgitation as their most troublesome symptom. Furthermore, 
the use of esomeprazole was found to be neither sensitive nor 
specific for the diagnosis of GERD in this study, clearly challeng-
ing the previously held adage that a proton pump inhibitor (PPI)
response test could help to distinguish patients with GERD from 
those with other conditions. This is disappointing, though not 
necessarily surprising. Evidence from a recent study of 2665 indi-
viduals from Russia, Brazil, the UK, and USA, in which patients 
were asked to describe symptoms in their own words, suggest that 
heartburn (as interpreted by clinicians) may encompass at least 
two distinct symptoms, potentially with different etiologies [9]. 
Indeed, the complex etiology of presumed reflux-induced symp-
toms is at the heart of issues with PPI response.
reflux–symptom relAtIonshIps And ppI 
response
The first indication that not all suspected GERD symptoms are 
caused by acid reflux came from Sifrim et al. in 1999, with the 
application of 24-h esophageal pH and multichannel intraluminal 
impedance monitoring in an experimental setting. This allowed 
reflux episodes to be detected regardless of their pH, and it was 
noted that only about half of reflux episodes detected in normal 
subjects using impedance monitoring were also detected by pH-
metry [10].
The majority of studies that actually quantify the extent to 
which non-acid (weak acid or weak alkaline) reflux contributes to 
symptoms in patients with GERD came after the Montreal Con-
sensus. These were recently reviewed to show that nearly a third 
(28%) of reflux-related symptoms are associated with non-acid 
reflux [11]. Similarly, a study by Savarino et al. found that in 87 
(38%) of 226 patients with heartburn and/or regurgitation occur-
ring at least three times a week, a positive association between 
reflux and symptoms (SAP > 95% [12]) was only observed if non-
acid reflux was also accounted for [13]. A positive SAP could not 
be achieved for any type of reflux in around a fifth of patients in 
this study [13].
The relative response of different symptoms to acid suppression 
therapy correlates with their dependence on acid (Fig. 1). While 
heartburn is more responsive than regurgitation to PPIs [14], both 
respond better to PPIs than chest pain, for which the therapeu-
tic response is minimal in unselected individuals (50% relief in 
0–17% of patients) [15]. However, chest pain responsiveness to 
PPIs increases substantially (50% relief in 56–85% of patients) if 
those with pathologic esophageal acid exposure are selected, indi-
cating that acid reflux can be a major contributor to this symptom, 
but that it is one of many possible causes [15]. Selecting patients 
with pathologic esophageal acid exposure also appears to improve 
the therapeutic gain of PPIs for chronic cough, though the shift 
in efficacy is very modest (from 0–9% to 12–36%) indicating that 
mechanisms behind this very common and fairly generic symp-
tom are even more heterogeneous than for chest pain, and largely 
unrelated to acid [16].
Given the above, it is not surprising that the proportion of 
reflux-related symptoms associated with non-acid reflux jumps 
drastically to around 80% in patients who experience symptoms 
despite taking a PPI [11]. A similarly dramatic increase in symp-
toms not related to any type of reflux is also observed, as shown 
in the seminal paper by Mainie et al. in which less than half of 
symptoms in 200 patients taking a PPI twice daily were related to 
reflux (8% acid and 35% non-acid) [17]. It should be noted that 
these figures incorporate both typical and atypical symptoms of 
GERD. Nevertheless, the proportion of patients who had a posi-
tive SAP for acid or non-acid reflux was low for the typical GERD 
symptoms of unexplained chest pain (18%), heartburn (30%), and 
regurgitation (52%) [17].
The relationship between sub-types of GERD and non-GERD 
conditions, reflux acidity, esophageal hypersensitivity (discussed 
later), and response to PPIs is shown in Fig. 2. Reflux is more often 
acidic in patients with reflux esophagitis than in those without 
[13, 18, 19], consistent with the strong causal link between reflux 
esophagitis and esophageal acid exposure [20]. Reflux esophagi-
tis is also, as one might expect, the most responsive of all GERD 
manifestations to acid suppression with PPIs [21, 22], with heal-
ing rates of over 80% (and possibly higher with prolonged treat-
ment [23]) [24]. Selecting patients with reflux esophagitis strongly 
selects for those with pathologic esophageal acid exposure. As 
such, the symptoms experienced by patients with reflux esophagi-
tis are more often related to acid and thus more responsive to PPIs 
than symptoms in patients without reflux esophagitis [13, 25, 26]. 
In addition, lower esophageal sensitivity to acid in patients with 
reflux esophagitis (particularly high grade) than in those with 
NERD [27] may lower the degree of acid suppression required to 
alleviate heartburn, also contributing to better PPI response. How-
ever, when patients without reflux esophagitis who have pathologic 
esophageal acid exposure are selected, the estimated complete 
symptom response rate with PPIs is comparable to that for reflux 
esophagitis [28].
Agents that have been shown to have some benefit in patients 
with PPI-resistant symptoms include alginates, mucosal protec-
tive agents, and baclofen. Alginates precipitate into a low-density 
viscous gel and have been shown to reduce the burden of reflux 
symptoms in patients with residual symptoms despite PPI use 
[29]. This may be because they can displace the acid pocket—an 
unbuffered zone of acid that forms postprandially in the stom-
ach, and which may not completely disappear with PPIs [30, 31]. 
Addition of a mucosal protection agent to PPI treatment has been 
shown to significantly improve symptoms and health-related 
quality of life compared with PPI alone in patients with NERD 
[32]. Furthermore, baclofen was found to reduce the number of 
reflux episodes (but not acid reflux episodes) in patients with PPI-
resistant symptoms via inhibition of transient lower esophageal 
sphincter relaxations [33], and to improve persistent symptoms 
associated with non-acid duodenal reflux in patients that were 
refractory to PPI treatment [34]. The therapeutic benefits of these 
drugs in patients with PPI-resistant symptoms may relate to their 
effects on residual pathologic acid, or on symptoms caused by 
non-pathologic acid or non-acid reflux due to reflux hypersensi-
tivity. Indeed, reflux hypersensitivity and functional heartburn are 
thought to account for most pain-related symptoms that persist 
despite PPI therapy.
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dIAGnosIs of reflux hypersensItIvIty And 
functIonAl heArtburn
As highlighted in a landmark review by Savarino et al., the com-
mon practice of identifying “NERD” patients solely on the basis 
of typical symptoms and an absence of reflux esophagitis selects 
for a heterogeneous patient group [35], of which only those where 
acid is implicated in symptom generation are clearly responsive 
to PPIs [36]. These groups consist of those with esophageal acid 
exposure (true NERD), normal esophageal acid exposure but a 
positive SAP for acid reflux (acid hypersensitive esophagus) or 
Suspected GERD-related symptoms
Cough
pH – pH + pH – pH + RE – RE + RE – RE +
Lowest HighestLikelihood of symptom response to acid suppression
Lowest HighestRole of acid reflux in symptom generation
Chest pain Regurgitation Heartburn
Fig. 1 Suspected gastroesophageal reflux disease (GERD)-related symptoms, their relative likelihood of response to acid-suppressive therapy based on the 
literature, and the presumed importance of acid reflux for symptom generation based on these findings. Smaller arrows underneath each symptom indicate 
the direction of the shift in response to acid suppression when patients are selected based on the presence (RE+) or absence (RE−) of reflux esophagitis, 
or the presence (pH+) or absence (pH−) of pathologic esophageal acid exposure. The relative position of each symptom and the size of the arrows is 
not to scale. In summary, heartburn is assumed to be the quintessential acid-related symptom and as such correlates the most frequently with pathologic 
esophageal acid exposure and response to acid-suppressive therapy. The response of heartburn (and regurgitation) to acid suppression is higher in RE+ 
patients than in RE− patients, concordant with RE being a good proxy for pathologic esophageal acid exposure in lieu of pH-testing. The relative response 
of symptoms to acid suppression decreases as their dependence on pathologic esophageal acid exposure decreases. However, even for symptoms such as 
chest pain and cough, response rates to acid suppression can be enhanced by identifying patients who have pathologic esophageal acid exposure (pH+), 
albeit with a dwindling effect as symptom etiology becomes increasingly multifactorial
GERD and non-GERD populations with heartburn
NAHE
AHE
FH
Lowest
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Fig. 2 Relationship between reflux acidity, response of heartburn to acid-suppressive therapy and the role of peripheral and/or central esophageal hy-
persensitivity in different gastroesophageal reflux disease (GERD) and non-GERD patients with heartburn. Reflux esophagitis (RE) correlates strongly with 
the presence of pathologic esophageal acid exposure and, concomitantly, healing of RE and heartburn resolution are high with acid-suppressive therapy 
in these patients. Some patients have heartburn but not RE. Those who have pathologic esophageal acid exposure (pH+) have NERD, and heartburn 
symptoms respond as well to acid suppression as they do in patients with RE. Those patients with heartburn who do not have pathologic esophageal acid 
exposure may still have a positive symptom association probability (SAP+) for acid or non-acid reflux, and are thus categorized as having reflux hypersensi-
tivity (acid hypersensitive esophagus (AHE) or non-acid hypersensitive esophagus (NAHE)). Patients without pathologic acid exposure who have a negative 
SAP are designated as having functional heartburn (FH). The role of peripheral and/or central esophageal hypersensitivity increases as dependence on 
acid reflux (and response to acid suppression) decreases, in line with heartburn perception occurring despite non-pathologic acid reflux (hyperalgesia) in 
patients with reflux hypersensitivity, or under physiological reflux conditions (allodynia) in patients with FH
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non-acid reflux (non-acid hypersensitive esophagus) and those 
with normal esophageal acid exposure and a negative SAP for any 
type of reflux (functional heartburn) [35]. This new understand-
ing is reflected in the most recent iteration of the Rome criteria 
(Rome IV) for functional esophageal disorders, in which the acid 
hypersensitive esophagus and non-acid hypersensitive esophagus 
groups have been combined into the new category of reflux hyper-
sensitivity, that would appear to fit somewhere between NERD 
and functional heartburn [7].
It should be noted that the SAP method was developed and vali-
dated in PPI-naive patients [12]. In the first study to determine the 
utility of the SAP method in patients with PPI-refractory symp-
toms (in whom it is most commonly employed in the clinic) it was 
determined that at reflux rates of <10%, SAP values were largely 
determined by chance, rather than by the relationship between 
symptoms and reflux. The same study also found that around 70% 
of patients who are refractory to PPIs have a reflux rate of <10% 
[37]. A more recent study by Choski et al. included a sub-group of 
patients with heartburn or regurgitation as their chief, PPI-refrac-
tory symptom [38]. In this study, the difference between patients 
diagnosed with acid reflux hypersensitivity and those diagnosed 
with functional heartburn, in terms of the number of symptoms 
associated with reflux, equated to only 1‒2 pressings per day of the 
symptom reporting button [38]. The authors did not include non-
acid reflux in their assessments, pointing out that this increases 
the probability of chance associations between symptoms and 
reflux episodes [38]. Other factors that could influence the accu-
racy of SAP include the shorter duration of impedance-detected 
reflux events versus acid-detected events [39], longer lag times for 
symptom perception after weakly acidic versus acid reflux [40], the 
potential for unreliable reporting of symptom timing by patients 
[41] and day-to-day variation in the onset of symptoms [38].
It remains to be seen whether reflux hypersensitivity should 
really be included as a functional esophageal disorder, given that 
its definition requires symptoms to be associated with reflux events 
[7]. This will likely be an area for future debate. For now though, 
only the mechanisms that may contribute to reflux hypersensitivity 
and functional heartburn will be discussed.
mechAnIsms of reflux hypersensItIvIty And 
functIonAl heArtburn
Individuals with reflux hypersensitivity may have impaired 
esophageal functioning compared with those with functional 
heartburn. In one study, the prevalence of microscopic esophagi-
tis, a potential marker of reduced mucosal integrity, was 65% in 
patients with reflux hypersensitivity, compared to 13% in patients 
with functional heartburn, and 15% in healthy volunteers [42]. In 
another study, esophageal mucosal integrity and the rate of esoph-
ageal chemical clearance were both reduced in PPI-responsive 
patients with reflux hypersensitivity compared with patients with 
functional heartburn and healthy volunteers [43].
The prevalence of microscopic esophagitis in patients with func-
tional heartburn is similar to the rate in healthy volunteers [42]. 
The rate of proximal reflux events and weak-acid reflux events is 
also similar in patients with functional heartburn and healthy vol-
unteers, but higher in those with reflux hypersensitivity [44]. These 
data reinforce the lack of any detectable, organic origins of func-
tional heartburn symptoms. Interestingly, microscopic esophagitis 
is more prevalent, and esophageal mucosal integrity and chemical 
clearance more greatly impaired in patients with GERD than in 
those with reflux hypersensitivity [42, 43]. These findings indicate 
that patients with reflux hypersensitivity experience heartburn 
despite comparatively (vs NERD and reflux esophagitis) greater 
mucosal protection of their esophageal receptors from chemical 
stimuli, invoking mechanisms of enhanced receptor sensitivity.
Peripheral and central hypersensitivity
Greater esophageal sensitivity to acid perfusion has been observed 
in patients with NERD compared with those with reflux esophagi-
tis [27, 45]. Patients with GERD and those with functional heart-
burn have also been shown to be more sensitive to esophageal 
balloon distension than healthy controls [46, 47]. Interestingly, 
several receptors theorized to be involved in transducing pain 
signals in response to acid are also sensitive to mechanical dis-
tention [48]. Esophageal distension caused by high reflux volume 
may therefore enhance the sensitivity of peripheral esophageal 
receptors to acid. Consistent with this, esophageal sensitivity to 
distension is enhanced in patients with GERD after perfusion 
of the esophagus with acid [47] and reflux symptom perception 
is enhanced in patients with NERD when gas (which enhances 
reflux volume) is present in reflux [49]. Repeated activation of 
peripheral esophageal receptors may also cause central sensiti-
zation of neurons in the dorsal horn of the spinal cord (central 
hypersensitivity), leading to both hyperalgesia (increased sensi-
tivity to pain cause by noxious stimuli) and allodynia (pain gen-
erated in response to physiological stimuli that do not normally 
cause pain) [50]. Central sensitization can lead to changes in the 
sensitivity of areas remote from the site of the initial acid exposure 
(secondary hypersensitivity) [50–52]. For example, acid perfu-
sion into the lower esophagus has been shown to reduce the pain 
threshold for subsequent electrical stimulation of the chest wall 
to a greater extent in patients with non-cardiac chest pain than in 
those without [52]. Secondary hypersensitivity may also contrib-
ute to the high prevalence of dyspeptic symptoms (around 40% 
[53]) in patients with GERD, as it provides a mechanism whereby 
gastroesophageal reflux may contribute to epigastric pain despite 
the latter being perceived as remote from the site of esophageal 
stimulation. Interestingly, dietary components may also play a 
role in central sensitization, with enhanced heartburn perception 
observed in one study after perfusion of fat into the duodenum, 
consistent with frequent reports by patients that diets high in fat 
worsen their symptoms [54].
Because central hypersensitivity (more than peripheral hyper-
sensitivity) is thought to contribute to allodynia [55], it may be of 
relevance to functional heartburn, which is by definition due to 
inappropriate pain responses to stimuli that are within the normal, 
physiological range. Evidence that central sensitization, whether 
caused by previous acid-related injury or other predisposing fac-
tors, may contribute to functional heartburn, comes from its 
overlap with functional disorders in other parts of the gut, such 
as irritable bowel syndrome and functional dyspeptic symptoms 
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[56–58]. In a recent post hoc analysis of pooled clinical trial data, the 
response of “substernal burning” to PPIs was found to be reduced 
if “dyspeptic-pain” was also present, possibly because the overlap 
of symptoms from different locations hints at a shared central 
sensitization (rather than acid reflux)-dominant etiology [59]. In 
addition, there is substantial laboratory-based evidence that symp-
toms experienced by patients with functional GI disorders can be 
induced or exacerbated with the administration of lipids [60].
A single dose of the selective serotonin reuptake inhibitor (SSRI) 
citalopram has been shown to reduce esophageal sensitivity to 
balloon distention and acid perfusion in healthy volunteers with 
established esophageal sensitivity [61]. SSRIs have been shown to 
significantly reduce symptoms compared with placebo in patients 
with reflux hypersensitivity (citalopram [62]) and patients with 
reflux hypersensitivity or functional heartburn (fluoxetine [63]) 
who are refractory to PPI treatment. In the only study to assess 
a tricyclic anti-depressant (imipramine) in patients with reflux 
hypersensitivity and functional heartburn, quality of life signifi-
cantly improved compared with placebo, but symptoms did not 
[64]. Histamine-2 receptor antagonists (H2RAs) have also been 
shown to modulate esophageal sensitivity to acid in patients with 
GERD [65], and patients with functional heartburn [66].
Psychological factors
The influence of the central nervous system extends to higher 
brain functions, with studies showing that psychological factors 
can increase the perception of heartburn (auditory stress [67] 
and life stress [68]) and esophageal pain (sleep deprivation [69]). 
Psychiatric comorbidity is high among patients with functional 
dyspepsia [70] and functional heartburn [71]. Indeed, it cannot be 
ruled out that SSRIs may exert some of their effects on heartburn 
perception (discussed above) indirectly, via their effects on anxi-
ety, mood, and sleep.
Mucosal barrier function
Microscopic esophagitis, as the name implies, refers to the pres-
ence of esophageal lesions that are only visible upon microscopic 
(rather than macroscopic, i.e., endoscopy) investigation. The 
presence of microscopic esophagitis may be a marker of impaired 
mucosal integrity due to chronic exposure of the esophageal 
mucosa to noxious reflux components, and thus also a marker 
of symptoms that are related to reflux. Studies have reported the 
ability to distinguish between patients with GERD (with heart-
burn) and those without [72], and between patients with NERD 
and those with functional heartburn [42], using global histol-
ogy scoring systems that combine the evaluation of a number 
of microscopic esophageal lesions (necrosis/erosion, neutrophil/
eosinophil intraepithelial infiltration, basal cell hyperplasia, elon-
gation of papillae, dilated intercellular spaces (DIS)). The main 
implication of these findings is that microscopic lesions may be 
a marker for impaired mucosal barrier function, which increases 
the exposure of peripheral esophageal receptors to reflux. In sup-
port of this pathophysiological mechanism, addition of a mucosal 
protection agent (a hyaluronic acid-chondroitin sulphate-based 
bioadhesive formulation) to PPI treatment was recently shown to 
improve symptoms and health-related quality of life to a signifi-
cantly greater extent than PPI alone in patients with NERD [32]. 
The idea that variation in the degree of exposure of peripheral 
receptors to refluxate contributes to symptom perception is fur-
ther supported by the recent observation that nociceptive sensory 
nerves are closer to the surface in the proximal and distal esopha-
gus of patients with NERD than in controls or patients with reflux 
esophagitis or Barrett’s esophagus [73]. An earlier study by the 
same group found these nerve fibers were closer to the surface at 
the proximal esophagus than at the distal esophagus [74], consist-
ent with the association of more proximal (vs distal) reflux with 
typical GERD symptoms [75–77].
Impaired esophageal mucosal barrier function has been shown 
to occur with DIS formation in response to acid or bile acids [78, 
79]. DIS formation and enhanced permeability of the esopha-
geal mucosal barrier occurs more readily in patients with NERD 
than in controls, suggesting an inherent susceptibility [79]. Fur-
thermore, while the resolution of DIS generally occurs in patients 
whose symptoms respond to PPI therapy, they tend to persist more 
in non-responders [80]. Increased penetration of weakly acidic or 
even alkaline reflux into esophageal tissue may mean that more 
receptors are exposed for longer, increasing the likelihood that 
symptom perception thresholds are reached. This is consistent with 
longer lag times for symptom perception following weakly acidic 
reflux compared with acid reflux [40]. It is interesting that stress, in 
addition to possibly increasing the perception of symptoms, may 
also induce DIS formation in the esophageal mucosa [81].
In the most recent (and largest) study to assess the diagnostic 
value of esophageal histology, total epithelial thickness was the 
best-performing criterion for identifying patients with investiga-
tion-defined GERD, and was also able to identify patients with 
NERD, reflux esophagitis, and pathologic esophageal acid expo-
sure [82]. DIS was not found to be a significant predictor of GERD. 
However, it is important to note that one of the main objectives of 
this study was to assess the level of agreement between assessors 
at the two pathology centres where the histologic examinations 
were performed using a refined global scoring system. In addi-
tion to being the best diagnostic criterion, total epithelial thick-
ness also had the best inter-observer agreement, suggesting that 
the success of this lesion in identifying patients with GERD may 
be at least partially due to the degree of reliability with which it 
can be assessed, rather than necessarily being more indicative of 
impaired mucosal status than other lesions. Total epithelial thick-
ness has subsequently been shown by the same group to enhance 
the diagnosis of GERD, particularly when concomitant epigastric 
pain is absent [83].
The inherent difficulties of identifying histologic markers that 
are both indicative of an impaired esophageal mucosal barrier and 
which can be assessed consistently across clinics, could be mooted 
by techniques that allow direct assessment of mucosal integrity. 
Impedance technology typically used to characterize reflux has 
been adapted to determine the baseline impedance of the esopha-
geal mucosa, a measure that correlates with transepithelial resist-
ance [84]. Both prolonged acid exposure [85, 86] and DIS [85, 
87] have been associated with lower esophageal baseline imped-
ance. Furthermore, it has been shown that baseline impedance is 
lower in patients with GERD (NERD and reflux esophagitis) than 
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in healthy volunteers [84] and can be used to distinguish patients 
with reflux esophagitis or NERD from those with functional 
heartburn [87]. Using baseline impedance overcomes several limi-
tations associated with the SAP, because accuracy should not be 
affected by variation in the reflux rate or temporal relationship 
between symptoms and reflux events, or the reliability of symptom 
reporting. Unfortunately, this approach is costly, cumbersome, 
and uncomfortable for the patient. However, more practical meth-
ods are being developed, at least two of which have shown high 
specificity and sensitivity for the diagnosis of GERD [88, 89]. It 
has also been suggested that baseline impedance could be useful 
for identifying patients in whom extra-esophageal symptoms are 
reflux related [90]. Indeed, there is a desperate need for diagnostic 
methods that can accurately identify patients with extra-esophageal 
GERD symptoms.
conclusIons And ImplIcAtIons
Our understanding of the processes that mediate symptom per-
ception and our ability to diagnose and treat symptoms decline 
rapidly as we move away from the more familiar territory of 
pathologic acid exposure, and into the hazier world of reflux 
hypersensitivity (to non-pathologic acid and non-acid reflux) 
and functional heartburn. Although reflux hypersensitivity and 
functional heartburn are not technically GERD [7], the complex 
array of tests required to identify these conditions hinders their 
exclusion in pragmatic clinical practice [91], where they account 
for the majority of the substantial symptom burden that exists 
despite PPI use [35, 92]. Indeed, clinical trials of reflux inhibi-
tor molecules developed to target symptoms that are refractory 
to PPIs have so far been thwarted, partly because symptom-based 
approaches to patient inclusion were used that do nothing to 
exclude patients with functional heartburn [93, 94].
Despite the poor relationship of even the typical symptoms of 
heartburn and regurgitation to pathologic acid reflux, treatment 
of suspected GERD symptoms with a PPI remains the best initial 
management approach. However, when PPI-resistant symptoms 
are encountered, an appreciation of the heterogeneous causes of 
suspected GERD symptoms becomes paramount. Without this, 
consequences may include assumptions of low adherence to PPIs 
that create barriers to further investigation, and referrals for sur-
gical interventions that may do little to address mechanisms that 
underlie functional heartburn, which at the moment can only 
be distinguished from NERD and reflux hypersensitivity with 
impedance–pH monitoring [35]. It is easy to imagine that a symp-
tom-based rationale for managing GERD, developed by expert con-
sensus and reinforced by excellent (though probably overestimated 
by physicians [95]) response rates for PPIs, might have reduced the 
treating physician’s appreciation of other symptom etiologies, espe-
cially when (unlike for acid reflux) there are no targeted treatments 
to reinforce the validity of other mechanisms. It would be inter-
esting to assess what impact (if any) the symptom-based Montreal 
Definition of GERD has had on physicians’ perceptions and man-
agement of symptoms that persist despite the use of PPIs.
Reflux hypersensitivity can theoretically involve mechanisms 
of impaired esophageal mucosal barrier function (leading to 
greater exposure of peripheral receptors to reflux components), 
sensitization of peripheral esophageal receptors, and central sen-
sitization which may occur due to repeated activation and input 
from peripheral receptors, or because of top–down inputs (e.g. 
stress), in either case leading the enhanced perception of stimuli. 
Heartburn becomes functional (rather than due to reflux hyper-
sensitivity) when it occurs in the presence of physiological levels 
of reflux, thus shifting the etiology towards enhanced perception 
rather than an enhanced stimulus. Based on this model, a patient 
with GERD could theoretically develop functional heartburn 
due to past, repeated activation of peripheral receptors by acid 
reflux. Upon treatment with a PPI, acid reflux may be resolved, 
but functional heartburn due to central sensitization may be 
unmasked. Indeed, there is no reason why any number of com-
binations of factors that contribute to symptoms could not exist 
in a single patient, and this consideration should be factored into 
management strategies.
Measuring symptoms is far easier to achieve on a large scale than 
the cumbersome physiological tests required to confirm if GERD 
is really present. As such, our most widely adopted assessments 
of the potential future prevalence of GERD are based on symp-
toms only [96]. But what version of symptom-based GERD will we 
actually be treating in the future? There is substantial evidence that 
increases in the prevalence of GERD symptoms are largely associ-
ated with increasing rates of obesity [97]. The most popular mech-
anistic view underlying this association is that abdominal obesity 
increases intra-abdominal pressure, which directly increases the 
propensity to reflux as well as promoting the development of hia-
tus hernia [98]. However, there is also evidence that symptoms 
experienced by patients with functional GI diseases are enhanced 
by dietary lipids, and an increasing role for stress in functional 
heartburn (i.e., central sensitization) and reflux hypersensitivity 
(DIS and peripheral and central sensitization) also needs to be 
considered. Changes over time in the distribution of factors that 
contribute to the symptoms used to diagnose GERD would also 
be expected to change the relative efficacy of different therapeutic 
approaches.
In conclusion, our base concepts, as espoused within the Mon-
treal Consensus, may now be a handicap in explaining and effec-
tively managing patients. We need a greater understanding of 
symptoms based on patients’ descriptors rather than clinicians’ 
categories to generate new targets for drug development and/or 
guide potential new applications for existing (or even discarded) 
drugs. Pragmatic tools must be developed to distinguish patients 
with GERD from those with reflux hypersensitivity and functional 
heartburn, for use in clinical trials of new drugs, and so that pop-
ulation-based prevalence estimates and risk factors can be more 
accurately determined. Importantly, these tools must be suffi-
ciently refined for use in pragmatic clinical practice, so it is feasible 
to target the appropriate drugs to the right patients. New methods 
for assessing esophageal mucosal integrity look promising, though 
other biomarkers (recently reviewed [99]) should continue to be 
investigated. However, even with such developments, the complex-
ity of symptoms and causes requires that the concept of GERD as a 
composite, symptom-based entity be re-evaluated, if more precise 
patient management is to be achieved.
© the Author(s) 2018 The American Journal of GastroenteroloGy
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